维胺酯胶囊和全反式维A酸霜治疗寻常痤疮临床疗效观察

目的:观察维胺酯胶囊和全反式维A酸霜(商品名:迪维霜)治疗寻常痤疮的疗效。方法:将寻常痤疮患者随机分成3组,A组口服维胺酯胶囊,外用0.025%迪维霜;B组外用0.025%迪维霜;C组口服多西环素(商品名:强力霉素),外用硫磺炉甘石洗剂。均各治疗6周。结果:A组对丘疹和脂溢的疗效优于B组和C组(P<0.05),对粉刺的疗效优于C组(P<0.001),对脓疱的疗效优于B组(P<0.05),对结节囊肿的疗效3组差异无显著性;综合疗效A组优于B组和C组(P<0.05);A组中中度痤疮患者的效果优于B组和C组(P<0.05),但对轻度痤疮3组差异无显著性。结论:口服维胺酯胶囊联合外用迪维霜治疗轻、中度痤疮疗效较好。     

维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效观察

目的：观察维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效及不良反应。方法：将396例寻常性痤疮患者随机分为两组。治疗组220例,口服维胺酯联合外用夫西地酸钠乳膏;对照组176例,口服维胺酯联合外用痤疮霜。8周后评价其疗效。结果：治疗组治愈率和总有效率分别为40.91%和89.09%,对照组治愈率和总有效率分别为30.68%和81.25%,治愈率和总有效率两组间比较差异有统计学意义（P〈0.05）。不良反应为局部皮肤轻度潮红,瘙痒,唇干。结论：维胺酯胶囊联合夫西地酸钠乳膏治疗寻常性痤疮疗效显著,不良反应少。     

异维A酸红霉素凝胶和维胺酯维E乳膏治疗寻常痤疮的随机平行对照研究

临床上各种外用维A酸制剂是治疗轻、中度寻常痤疮首选的方法之一,也是痤疮维持治疗的主要药物.此外,外用过氧化苯甲酰制剂和外用抗生素制剂也是治疗寻常痤疮的重要方法,其中外用红霉素是较常用的方法[1].有报道外用异维A酸制剂和红霉素联合使用有协同作用[2],而外用异维A酸的不良反应比外用全反式维A酸低[3].本试验使用异维A酸红霉素凝胶治疗寻常痤疮,观察其疗效和不良反应,并和维胺酯维E乳膏比较.     

口服维胺酯与异维A酸治疗寻常性痤疮临床观察

目的 观察三蕊维胺酯胶囊及异维A酸胶丸分别与0．025％维A酸霜合用时对寻常痤疮的疗效比较。方法 将100例寻常痤疮患者随机分成2组，治疗组口服三蕊维胺酯胶囊，对照组口服异维A酸胶丸，并且均同时合用0．025％维A酸霜，疗程6周。结果 治疗组对粉刺、丘疹、脓疱、结节、脂溢程度的疗效与对照组相当，差异无显著性，不良反应发生率治疗组(22％)低于对照组(34％)，但无统计学意义。结论 口服三蕊维胺酯胶囊联合外用0．025％维A酸霜是治疗寻常痤疮的有效方法。     

维胺酯胶囊和盐酸米诺环素治疗囊肿性痤疮临床疗效观察

为观察维胺酯胶囊和盐酸米诺环素治疗囊肿性痤疮的疗效，将囊肿性痤疮患者随机分成3组，A组口服维胺酯胶囊和盐酸米诺环素；B组口服维胺酯胶囊；C组口服盐酸米诺环素。均治疗8周。A组对粉刺、丘疹和脓疱的疗效优于C组（P〈0．05），对结节和囊肿的疗效优于B组（P〈0．05）；综合疗效A组优于B组和C组（P〈0.05）：维胺酯胶囊和盐酸米诺环素联合治疗囊肿性痤疮较两药单独治疗可明显提高疗效。     

皮脂腺及皮下脂肪疾病

20070921 细胞免疫和体液免疫在寻常性痤疮发病中的作用；20070922综合治疗寻常型痤疮120例疗效分析；20070923 皮肤美容护理结合外用药物治疗寻常痤疮疗效观察；20070924 维胺酯和异维A酸治疗寻常痤疮随机双盲研究；20070925 2％水杨酸凝胶治疗寻常痤疮的随机双盲对照研究；[编按]     

火针联合红蓝光治疗中度寻常型痤疮疗效观察

目的:观察火针联合红蓝光照射治疗中度寻常型痤疮的临床疗效。方法:将符合入选标准的180例患者随机分为两组,试验组95例,对照组85例。试验组采用火针联合红蓝光照射治疗,火针治疗1~2周1次,红蓝光治疗每周1次;对照组用红蓝光照射联合维胺酯口服治疗,红蓝光照射每周1次,口服维胺酯50 mg/次,3次/日。8周后观察并比较两组疗效。结果:实际完成试验患者共173例:试验组92例,总有效率为83.70%;对照组81例,总有效率为64.20%,两组疗效差异有统计学意义(2=8.64,P=0.003)。结论:火针联合红蓝光照射治疗用于中度寻常型痤疮疗效较好,不良反应少,具有临床推广价值。     

皮脂腺及皮下脂肪疾病

微晶磨削与胶原蛋白膜联合治疗痤疮后凹陷性瘢痕;达英-35联合阿奇霉素治疗女性迟发性痤疮;中西药结合治疗寻常痤疮临床疗效观察;冰黄肤乐软膏联合维A酸霜治疗寻常痤疮疗效观察;桑贝冲剂联合维胺酯胶囊治疗寻常痤疮临床观察;中药粉刺方内眼外用治疗寻常性痤疮的临床观察；     

美他环素联合新癀片治疗寻常痤疮临床观察

目的评价美他环素联合新癀片治疗中、重度寻常痤疮的疗效与安全性。方法入选患者随机分为A组、B组和C组。A组口服盐酸美他环素胶囊0.2g,2次/d;新癀片1.28g,3次/d。B组口服盐酸美他环素胶囊0.2g,2次/d。C组口服盐酸米诺环素胶囊50mg,2次/d。三组患者同时外用维胺酯维E乳膏,每晚1次。疗程均为6周。于治疗前及治疗后第1、2、4和6周时分别计数皮损,观察疗效和不良反应。结果治疗2周和4周时,A组临床疗效均明显好于其他两组,差异有统计学意义(P<0.05);治疗结束时,各组均有75%以上的患者达到了基愈或显效,A组的有效率达到了90.1%。结论美他环素联合新癀片治疗寻常痤疮起效较快,疗效较好,耐受性良好。     

皮脂腺及皮下脂肪疾病

20062143维胺酯胶囊联合罗红霉素治疗中重度痤疮疗效观察/李志坚(广东佛山市皮防所)∥岭南皮肤性病科杂志.-2005,12(4).-322,332治疗组40例,口服维胺酯胶囊50mg,罗红霉素片150mg,均2次/d;对照组36例,口服罗红霉素片150mg,2次/d。两组均外用氯霉素酒精,疗程均6周。结果:治疗组有效率92·5%,显著高于对照组69·44%(P<0·05)。表1参3(张国平)20062144多西环素联合维胺酯治疗痤疮疗效观察/张华黎(新乡医学院三附院皮肤科),王威∥中国美容医学.-2006,15(4).-444~445将100例寻常痤疮患者随机分成两组:治疗组口服维胺酯胶囊50mg3次/d,连服2周,后改…     

Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial

New combination topical formulations for the treatment of acne may improve outcomes by increasing adherence. We assessed adherence to and efficacy of a combination topical medication for acne applied once daily compared with daily applications of 2 separate generic subcomponents. Twenty-six participants with mild to moderate acne vulgaris were randomized to 12 weeks of once daily application of clindamycin phosphate 7.2%-tretinoin 0.025% gel (CTG) combination product or separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream) for a total of 2 applications daily. Disease severity was measured at baseline and weeks 4, 8, and 12. Adherence was monitored using electronic monitoring caps on the medication tubes. Of the 26 participants enrolled, 21 completed the 12-week study. Median adherence in the CTG group was 88% compared with 61% in the C gel + T cream group. There was a 51% mean reduction in total lesions for the CTG group versus a 32% mean reduction for the C gel + T cream group by the end of the study. Both CTG and separate applications of C gel + T cream improved mild to moderate acne. The use of a once daily combination product has the advantage of promoting better adherence and clinical outcomes.     

Randomised,controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris

BACKGROUND: Previous clinical trials have shown that adapalene gel produces less irritation than tretinoin gels and tretinoin 0.025% cream. Short term results have shown that adapalene is less irritating than tretinoin gels and creams. This study is the first to compare the 0.1% formulation of adapalene gel with the 0.05% strength of tretinoin cream in a formal clinical trial. OBJECTIVE: To investigate the efficacy and tolerability of adapalene gel 0.1% compared with tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris. METHODS: Ten-week, multicentre, randomised, investigator-masked, active-controlled, parallel group study in 409 patients with acne vulgaris. RESULTS: Adapalene gel 0.1% demonstrated equivalent efficacy in reduction of acne lesion counts and global improvement of acne severity over 10 weeks' treatment and was significantly better tolerated than tretinoin cream 0.05% in terms of erythema, dryness, desquamation and stinging/burning. CONCLUSION: Adapalene gel 0.1% showed equivalent efficacy and was significantly better tolerated than tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris.     

红蓝光治疗面部轻中度痤疮疗效观察

目的观察红蓝光联合治疗面部痤疮患者的临床疗效和安全性。方法将108例轻、中度痤疮患者随机分成2组,试验组68例采用红蓝光照射联合外用克林霉素磷酸酯凝胶治疗;对照组40例单独应用克林霉素磷酸酯凝胶治疗。于治疗前及治疗第4周、第8周评价疗效及不良反应。结果治疗4周时试验组痊愈率为11.76%,有效率为61.76%;对照组痊愈率7.5%,有效率42.5%,两组差异有统计学意义(P<0.05);治疗8周时实验组痊愈率为23.53%,有效率为85.29%;对照组痊愈率10%,有效率47.5%,两组差异有统计学意义(P<0.05)。实验组与对照组均无明显不良反应。结论应用红蓝光照射治疗轻、中度面部寻常性痤疮安全有效。     

15 % Azelainsäuregel in der Behandlung der Akne. Zwei doppelblinde klinische Vergleichsstudien

Background: Topical measures are still the mainstay in the therapy of mild‐to‐moderate acne vulgaris. Azelaic acid 20 % in a cream formulation has been established as an efficacious and safe topical drug for 15 years. A new non‐alcoholic hydrogel formulation containing 15 % azelaic acid was clinically tested against two standard drugs – 5 % benzoyl peroxide (BPO) and 1 % clindamycin. Patients and Methods: In two independent, randomized, blinded comparative trials 15 % azelaic acid gel was clinically tested against 5 % benzoyl peroxide (BPO) gel in 351 patients and against 1 % clindamycin gel in 229 patients. The drugs were applied b. i. d. for 4 months. Results: Azelaic acid 15 % gel proved to be as effective as BPO and clindamycin with median % reduction of the inflamed lesion (papules and pustules) of 70 %, and 71 % respectively. The azelaic acid gel was well‐tolerated, the side effects (local burning and irritation) were distinctly less than with BPO but more pronounced than with clindamycin. Despite these side effects, the treatment was well‐accepted by the majority of patients. Conclusions: Azelaic acid gel is an effective topical monotherapy for mild‐to‐moderate acne vulgaris; its new gel form is an enrichment of acne therapy.     

Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris

Topical retinoids are the cornerstone of therapy for acne vulgaris. Nevertheless, the adjunctive use of other anti-acne agents can help enhance the efficacy of topical retinoids still further. Given that tazarotene 0.1 percent gel has previously shown significantly greater efficacy than tretinoin 0.025 percent gel, it is likely that tazarotene plus clindamycin offers superior efficacy to tretinoin plus clindamycin, which has recently become available as a combination product. A total of 150 patients with facial acne vulgaris were randomly assigned to receive either tazarotene 0.1 percent cream plus clindamycin 1 percent gel, or tretinoin 0.025 percent gel plus clindamycin 1 percent gel. Each medication was applied once daily in the evening (clindamycin followed by the retinoid 5-10 minutes later) for up to 12 weeks. At week 12, the reduction from baseline in lesion counts was greater with tazarotene/clindamycin than tretinoin/clindamycin for both the non-inflammatory lesion count (71% vs. 52%, p< or =.01) and the inflammatory lesion count (77% vs. 67%, P=.053). Tazarotene/clindamycin also resulted in a significantly higher incidence of patients achieving > or = 50 percent global improvement (incidence of 88% vs. 75% at week 12; p< or =.05). Both regimens were similarly well tolerated. In the treatment of facial acne vulgaris, tazarotene plus clindamycin offers significantly greater efficacy than tretinoin plus clindamycin and has comparable tolerability.     

当归苦参丸联合红蓝光和维A酸乳膏治疗中度痤疮疗效评价

目的:评价当归苦参丸联合红蓝光、维A酸乳膏治疗中度痤疮的临床疗效和安全性。方法:将入选的118例中度痤疮患者随机分成2组,治疗组(60例)给予当归苦参丸联合红蓝光、维A酸乳膏治疗,对照组(58例)给予红蓝光联合维A酸乳膏治疗,2组患者疗程均为4周。治疗结束时评价两组患者的临床疗效。结果:治疗组与对照组有效率分别为81.60%和55.17%,差异有统计学意义(P0.05)。结论:当归苦参丸联合红蓝光及维A酸乳膏治疗中度痤疮安全有效。     

1 percent clindamycin phosphate solution versus 5 percent benzoyl peroxide gel in papulopustular acne

In a multicenter study, 60 patients suffering from mainly moderate papulopustular acne were treated to pically either with 1% clindamycin phosphate in alcoholic solution or with 5% benzoyl peroxide gel, 30 patients each. During the treatment period of 9 weeks, clinical controls with lesion counts were performed every 3 weeks and after a 3 weeks follow-up. The therapeutic efficacy according to the reduction of papules and pustules was 72% in the benzoyl peroxide group and 73% in the clindamycin group, the latter showing significantly less side effects. On account of its good therapeutic results, we consider topical treatment with clindamycin phosphate an important alternative to systemic antibiotic or topical benzoyl peroxide therapy in acne.     

Topical clindamycin versus systemic tetracycline in the treatment of acne: Results of a multiclinic trial

In a multiclinic double-blind trial, 305 patients with moderate to severe acne vulgaris were treated with oral tetracycline hydrochloride, 250 mg (N: 103), a 1% solution of clindamycin phosphate (N: 105), or placebo (N: 97) twice daily for 8 weeks. The response to treatment was evaluated by lesion counts and overall clinical improvement at 2, 4, 6, and 8 weeks. Both topical clindamycin and oral tetracycline significantly reduced papule and pustule counts compared to placebo; they were rated significantly higher than placebo on the physician's and the patient's overall evaluation at the end of the treatment period. No serious side effects were reported with any of the study medications.     

Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study

Taurine bromamine (TauBr), the product of taurine and hypobromous acid (HOBr), exerts anti-inflammatory and antibacterial properties. Recently we have shown that Propionibacterium acnes, a potential pathogenic agent of acne, is extremely sensitive to TauBr. As topical antibiotics are associated with the emergence of resistant bacteria, TauBr seems to be a good candidate for topical therapy for acne vulgaris. In our double blind investigation, the efficacy and safety of 3.5 mM TauBr cream was evaluated. 1% Clindamycin gel (Clindacin T), one of the most common topical agents in the treatment of acne vulgaris, was used as a control. Forty patients with mild to moderate inflammatory facial acne vulgaris were randomly treated with either TauBr or clindamycin for 6 weeks, twice-a-day. More than 80% of the patients markedly improved with both treatments, without any adverse effects observed. Both TauBr and clindamycin produced a significant reduction in inflammatory skin lesion counts (papules/ pustules). After 6 weeks, comparable reductions of acne lesions, 65% and 68%, were observed in the TauBr and clindamycin groups, respectively. In conclusion, these data support our concept that TauBr can be used as a topical agent in the treatment of acne vulgaris, especially in patients who have already developed antibiotic resistance.